MDXG vs. PRCT, NVST, LIVN, WRBY, NVCR, LMAT, EYE, ENOV, CNMD, and TNDM
Should you be buying MiMedx Group stock or one of its competitors? The main competitors of MiMedx Group include PROCEPT BioRobotics (PRCT), Envista (NVST), LivaNova (LIVN), Warby Parker (WRBY), NovoCure (NVCR), LeMaitre Vascular (LMAT), National Vision (EYE), Enovis (ENOV), CONMED (CNMD), and Tandem Diabetes Care (TNDM). These companies are all part of the "medical equipment" industry.
MiMedx Group vs. Its Competitors
PROCEPT BioRobotics (NASDAQ:PRCT) and MiMedx Group (NASDAQ:MDXG) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.
89.5% of PROCEPT BioRobotics shares are owned by institutional investors. Comparatively, 79.2% of MiMedx Group shares are owned by institutional investors. 6.6% of PROCEPT BioRobotics shares are owned by company insiders. Comparatively, 1.7% of MiMedx Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
PROCEPT BioRobotics has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500.
PROCEPT BioRobotics currently has a consensus price target of $90.00, suggesting a potential upside of 51.22%. MiMedx Group has a consensus price target of $12.50, suggesting a potential upside of 98.89%. Given MiMedx Group's stronger consensus rating and higher probable upside, analysts plainly believe MiMedx Group is more favorable than PROCEPT BioRobotics.
MiMedx Group has a net margin of 11.40% compared to PROCEPT BioRobotics' net margin of -36.20%. MiMedx Group's return on equity of 22.70% beat PROCEPT BioRobotics' return on equity.
In the previous week, PROCEPT BioRobotics had 3 more articles in the media than MiMedx Group. MarketBeat recorded 5 mentions for PROCEPT BioRobotics and 2 mentions for MiMedx Group. PROCEPT BioRobotics' average media sentiment score of 0.49 beat MiMedx Group's score of 0.00 indicating that PROCEPT BioRobotics is being referred to more favorably in the media.
MiMedx Group has higher revenue and earnings than PROCEPT BioRobotics. PROCEPT BioRobotics is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.
Summary
MiMedx Group beats PROCEPT BioRobotics on 10 of the 16 factors compared between the two stocks.
Get MiMedx Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDXG and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MDXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MiMedx Group Competitors List
Related Companies and Tools
This page (NASDAQ:MDXG) was last updated on 7/3/2025 by MarketBeat.com Staff
